BiomericaBMRA
BMRA
About: Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates in one segment namely, the design, development, marketing and sales of diagnostic kits. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
Employees: 64
0
Funds holding %
of 7,139 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
1.3% less ownership
Funds ownership: 9.66% [Q3] → 8.36% (-1.3%) [Q4]
16% less funds holding
Funds holding: 25 [Q3] → 21 (-4) [Q4]
21% less capital invested
Capital invested by funds: $533K [Q3] → $421K (-$112K) [Q4]
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
Research analyst outlook
We haven’t received any recent analyst ratings for BMRA.
Financial journalist opinion
Neutral
GlobeNewsWire
2 days ago
Biomerica's inFoods® IBS Clinical Trial Results Published and Featured in Gastroenterology, the Leading GI Medical Journal
IRVINE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global leader in advanced medical diagnostic solutions, is proud to announce that patients with Irritable Bowel Syndrome (IBS) may experience significant relief from abdominal pain when following a dietary therapy created and guided by the inFoods® IBS blood test. The findings from a clinical trial published in Gastroenterology , demonstrate that participants who adhered to a personalized diet therapy based on the test results experienced greater symptom improvement compared to those following a sham (placebo) elimination diet.
Positive
Benzinga
1 month ago
Biomerica Stock Trades 200% Higher After Prostate Screening Test Receives Approval
Biomerica, Inc. BMRA stock is surging with a session volume of 139.2 million as per data from Benzinga Pro.
Neutral
GlobeNewsWire
1 month ago
United Arab Emirates Ministry of Health and Prevention Approves Biomerica's Fortel® PSA Screening Test to Detect an Early Sign of Prostate Cancer
- 10-Minute PSA Test for Early Detection of Prostate Specific Antigen (PSA), an Early Warning Sign of Prostate Cancer
Neutral
GlobeNewsWire
1 month ago
Biomerica Reports Second Quarter Fiscal 2025 Financial Results
- Total Revenue Increases 5% Year-Over-Year - Achieves Sustained Revenue Growth, Improved Gross Margins, and Significant Cost Savings IRVINE, Calif., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the second quarter of fiscal 2025 ended November 30, 2024.
Neutral
GlobeNewsWire
3 months ago
Biomerica Secures Three Key International Patents for inFoods® Technology to Address GERD, Crohn's Disease, and Ulcerative Colitis
IRVINE, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA), a global biomedical technology company, announces they have recently received three patent notices of allowance covering technology and methods for treating Gastroesophageal Reflux Disease (“GERD”), Crohn's Disease, and Ulcerative Colitis using its proprietary inFoods® Technology. These patents apply to countries under the European Patent Organization (“EPO”), including major markets such as Germany, UK, France, Italy, and Spain, as well as over 30 other nations within the EPO.
Neutral
GlobeNewsWire
3 months ago
Nasdaq grants Biomerica an additional 180 days to meet listing compliance requirements
IRVINE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a leading global provider of advanced medical diagnostics, announced that it has been granted an additional 180-day compliance period from the Nasdaq Stock Market LLC ("Nasdaq") to meet the minimum $1.00 per share bid price requirement for continued listing on the Nasdaq Capital Market. This extension allows Biomerica until May 5, 2025, to regain compliance.
Neutral
GlobeNewsWire
3 months ago
Biomerica Announces Direct-to-Consumer Availability of inFoods® IBS Test, Targeting Relief for Bloating and Gastrointestinal Pain
IRVINE, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a leading global provider of advanced medical diagnostics, is excited to announce a major enhancement to its inFoods® IBS platform. US consumers can now seamlessly order the inFoods® IBS test directly from infoodsibs.com and consequently collect a sample in the comfort of their home. As part of this ordering process, a licensed physician remotely authorizes the test, ensuring professional medical oversight, without the need for visiting a doctor's office.
Neutral
GlobeNewsWire
4 months ago
Biomerica Reports First Quarter Fiscal 2025 Financial Results
IRVINE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical diagnostic and therapeutic products today reported financial results for the first quarter of fiscal 2025 ended August 31, 2024.
Neutral
GlobeNewsWire
5 months ago
The Saudi Food and Drug Authority (SFDA) Approves Biomerica's At Home PSA Screening Test to Detect Early Signs of Prostate Cancer
- 10-Minute At-Home PSA Test for Early Detection of Prostate Cancer - First order already shipped to Saudi Arabia - Prostate Cancer is the Second Most Common Cancer in Men Globally IRVINE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) is pleased to announce that the Saudi Food and Drug Authority (SFDA) has approved the Company's Fortel® Prostate (PSA) Screening Test to be sold and used in the country.
Neutral
GlobeNewsWire
5 months ago
Biomerica Reports Fiscal 2024 Year End Results
IRVINE, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Biomerica, Inc. (NASDAQ: BMRA) today reported its financial results for the fiscal year ended May 31, 2024. The Company achieved a modest increase in net sales to $5.4 million, compared to $5.3 million in the prior year. This growth was primarily driven by strong demand for EZ Detect™ colorectal screening tests and Aware® breast self-exam products in the Middle East including the United Arab Emirates.
Charts implemented using Lightweight Charts™